Cassaday & Co Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.95K	Buy	+960	New	+$3.71K	﹤0.01%	1035

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cassaday & Co Wealth Management's RXRX Position: Q1 2026 in Review

Cassaday & Co Wealth Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 960 shares worth $2.95K. The stake represents ﹤0.01% of the portfolio and ranks #1035 among its holdings.

334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Cassaday & Co Wealth Management held 960 shares of Recursion Pharmaceuticals worth $2.95K as of Q1 2026.
Recursion Pharmaceuticals was a new Cassaday & Co Wealth Management position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #1035 holding.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.